close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc. Common Stock (NY:BHC)

6.200 -0.180 (-2.82%)
Official Closing Price Updated: 7:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Bausch Health Companies Inc. (BHC) Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Bausch Health Companies Inc. (BHC) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Bausch Health Companies Inc. (BHC) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients
Via ACCESSWIRE
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
Via ACCESSWIRE
Why Shares of Bausch Health Jumped on Friday
Global investment powerhouse KKR will be providing the healthcare company with increased liquidity. 
Via The Motley Fool
The Law Offices of Frank R. Cruz Announces Investigation of Bausch Health Companies Inc. (BHC) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
BAUSCH HEALTH COMPANIES INC. (NYSE: BHC) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch Health Companies Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Bausch Health Companies Inc. (BHC)
From Robbins LLP
Via Business Wire
Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023
Via ACCESSWIRE
Why Bausch Health Companies Stock Is Tanking Today
The never-ending saga over generic Xifaxan is weighing on the drugmaker's stock today. 
Via The Motley Fool
BHC EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BHC
From The Rosen Law Firm, P.A.
Via Business Wire
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived... 
Via Benzinga
Why Shares of Bausch Health Soared Wednesday
The company won a big patent fight with a generic-drug maker. 
Via The Motley Fool
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
Via ACCESSWIRE
Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3
Via ACCESSWIRE
Breather For Carl Icahn: Revised Loan Agreements and Recovery Strategy Post Short-Seller Attack
Activist investor Carl Icahn has been struggling to recover after a short-seller attack led to a 40% drop in his investment company's shares, Icahn Enterprises L.P. (NASDAQ: IEP), alarming major banks... 
Via Benzinga
OraPharma to Participate in the First-Ever Research and Technology Pavilion Sponsored by Pacific Dental Services(R) at the American Dental Hygienists' Association (ADHA(R)) Annual Conference
Via ACCESSWIRE
Bausch Health Enters Into $600 Million Financing Facility With KKR
Via ACCESSWIRE
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE: 
Via Benzinga
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023
 
Via Benzinga
Coinbase, Blue Bird, Tingo Group And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mixed, with the Nasdaq Composite rising around 0.2% on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Recruiter.com Group, Inc. (NASDAQ: RCRT) shares jumped 114% to $0.41. Recruiter.com signed a definitive agreement for planned purchase of fintech assets of GoLogiq. 
Via Benzinga
Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration
Via ACCESSWIRE
Zoetis Declares New Dividend, Hinting At Undervaluation
Zoetis shareholders woke up to news of JAB's acquisition of Pumpkin, a per insurance platform where Zoetis owns a minority stake. 2023 outlooks suggest a rally 
Via MarketBeat
Bausch Health Options Traders: Stock Will Remain Below This Level Through July Expiration
Bausch Health Companies Inc. (NYSE: BHC) shares rose sharply on Wednesday. 
Via Benzinga
New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis
Via ACCESSWIRE
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Via ACCESSWIRE
Bausch Health Observes Mental Health Awareness Month
Via ACCESSWIRE
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today